Search the Newsreel

Chemomab Therapeutics Ltd (CMMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Chemomab Therapeutics Ltd (CMMB) stock, focusing on various indicators and moving averages. It presents a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and TRIX, alongside moving averages like MA5 and MA10. …

Is Broker Upgrades And Zacks Rank #1 Status Altering The Investment Case For Chemours (CC)?

Chemours (CC) has received broker upgrades and a Zacks Rank #1, signaling increased confidence in its earnings growth. While this strengthens the recovery thesis for the specialty chemicals company, investors must still consider ongoing environmental and litigation risks, particularly regarding PFAS liabilities. These risks …

Chemomab Therapeutics Ltd (CMMB) Institutional Confidence

This article provides details on the institutional confidence in Chemomab Therapeutics Ltd (CMMB), including its stock performance and key shareholder activities. It lists several institutional and individual shareholders, along with the shares they hold and their percentage change. The stock closed at $1.410 with …

US environmental groups urge EPA to reject new Pfas to cool datacenters

A coalition of 17 environmental groups is urging the EPA to reject Chemours' application to fast-track a new PFAS chemical, Opteon 2P50, for use in cooling datacenters. The groups accuse Chemours of downplaying health and climate risks, arguing that the chemical is likely more …

Chemomab Therapeutics Ltd

This article provides an overview of Chemomab Therapeutics Ltd (CMMB) stock performance, showing a closing price of $1.360 with a -2.86% change. It highlights that critical revenue breakdown data by business segments and regions have not yet been disclosed by the company. The page …

Chemomab Therapeutics Ltd (CMMB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Chemomab Therapeutics Ltd (CMMB). It notes that no dividends have been distributed over the past five years, but lists several stock splits, including a 4:1 merger in August 2025 and multiple 16:1 mergers in …

Chemomab Therapeutics Ltd (CMMB) Valuation: PE, PB & Fair Value Analysis

This article provides a brief valuation analysis for Chemomab Therapeutics Ltd (CMMB), noting key financial metrics. As of the close on July 24th, CMMB had a market cap of $39.17 million and a P/E TTM of 7.81. However, specific P/E, P/B, and P/CF data …

Chemomab Therapeutics Ltd (CMMB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Chemomab Therapeutics Ltd (CMMB), focusing on volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return Best/Worst Daily Return, Sharpe Ratio, Skewness, Realised Volatility, Standardised True Range, Downside …

Chemomab Therapeutics Ltd. Revenue Breakdown – NASDAQ:CMMB

This article provides financial information for Chemomab Therapeutics Ltd. (NASDAQ: CMMB) on TradingView. It indicates that the market is closed with no recent trades. The content focuses on an overview of financial data, segments, and other fundamental statistics for the company.

CMMB|Chemomab Therapeutics Ltd|Price:1.800|Chg%:+0.050

This article provides a stock score and comprehensive analysis of Chemomab Therapeutics Ltd (CMMB) from TradingKey. It details how TradingKey generates its stock scores across six dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment. The article states that …

Federal Chemours settlement raises questions for Bladen County

A proposed federal settlement regarding Chemours' Fayetteville Works plant has raised concerns in Bladen County about its impact on local residents, agriculture, and environmental health. While the settlement includes a civil penalty and additional pollution controls, it doesn't specify how much funding will directly …

3 Stocks Worth Buying After Recent Broker Ratings Upgrade

This article highlights three stocks—PENN Entertainment (PENN), The Chemours Company (CC), and Lumentum Holdings Inc. (LITE)—that have recently received broker rating upgrades, suggesting strong upside potential. The recommendations are based on a comprehensive screening strategy that includes significant broker rating upgrades, stock price thresholds, …

Reliance Chemotex Industries Share Price Forecast to 2030

Chemours Company (0HWG) Q4 2023 Earnings Report - Results, Call & Slides

The Chemours Company (0HWG) reported its Q4 2023 earnings, surpassing analyst expectations with an actual EPS of $0.31 against a consensus of $0.27 and revenue of $1.36 billion compared to an expected $1.32 billion. The company also announced a 1.72% year-over-year revenue growth. Details …

Chemours Announces Dates for Second Quarter 2026 Earnings Release and Webcast Conference Call

WILMINGTON, Del., July 23, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC) today announced that the Company expects to issue its second quarter 2026 financial results after market on Tuesday, August 4, 2026. The Company expects to hold its conference …

Chemours Expects a Public Q2 Results Webcast Aug. 5

Chemours (NYSE: CC) announced it would release its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026, with a public webcast conference call scheduled for 8:00 a.m. EDT on Wednesday, August 5, 2026. Investors can access the live webcast, accompanying slides, …

Chemours (CC) Pulls Back As Bullish Valuation Holds, Is The Stock Still Cheap?

Chemours (CC) stock has recently pulled back by 15% over 30 days and 24.6% over 90 days, despite a 48.9% year-to-date return. Bullish analysts value the company at $30, suggesting it's undervalued compared to its current price of $18.24, based on projected revenue growth …

Chemours earnings on deck as investors eye margin recovery By Investing.com

Chemours Co. is expected to report a significant sequential rebound in its second-quarter earnings, with analysts forecasting 50 cents per share on $1.66 billion in revenue. Investors will be closely watching the company's margin trajectory, its ability to sustain pricing in the Titanium Technologies …

Chemours Settles PFAS Lawsuit for $450 Million

Chemours has agreed to a $450 million settlement with the Environmental Protection Agency (EPA), Department of Justice (DOJ), and West Virginia Department of Environmental Protection over PFAS contamination in several rivers. While the settlement includes civil penalties and mitigation efforts, it controversially permits Chemours …

Chemours lawsuit settlement: Another round of destructive environmental denialism

The article criticizes a proposed settlement by the Trump EPA regarding the Chemours GenX and PFAS lawsuit, arguing it downplays environmental crises and offers inadequate remediation. North Carolina officials, including Attorney General Jeff Jackson and Governor Josh Stein, have denounced the settlement, stating it …

SIG or CFRUY: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Retail - Jewelry sector might want to consider either Signet (SIG) or Compagnie Financiere Richemont AG (CFRUY). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone …

Chemomab Therapeutics (CMMB) Q4 2025 earnings summary

Chemomab Therapeutics reported its Q4 2025 earnings, highlighting a positive FDA End-of-Phase 2 meeting for nebokitug in PSC, paving the way for a single Phase 3 trial. The company also announced strong financial management with a cash runway expected through Q1 2027 and reduced …

Chemomab Therapeutics (CMMB) H.C. Wainwright 27th Annual Global Investment Conference summary

Chemomab Therapeutics (CMMB) presented positive Phase II results for nebokitug, a potential first-in-class treatment for primary sclerosing cholangitis (PSC), at the H.C. Wainwright 27th Annual Global Investment Conference. The drug met safety and efficacy endpoints, leading to FDA alignment for a single pivotal Phase …

Bernstein erhöht Kursziel und Prognosen für Richemont nach starkem Ergebnis im 1. Geschäftsquartal

HBM boosts Chemomab Therapeutics Ltd. (CMMB) stake amid Scipher merger plan

HBM Healthcare Investments (Cayman) Ltd. has significantly increased its beneficial ownership in Chemomab Therapeutics Ltd. (CMMB) to approximately 12.5%, amidst Chemomab's planned merger with Scipher Medicine Corporation. HBM will vote its shares in favor of the merger, which includes contingent value rights for current …

AG Jeff Jackson calls on residents for feedback on EPA-Chemours settlement

North Carolina Attorney General Jeff Jackson is urging state residents to submit comments to the Environmental Protection Agency regarding its settlement with Chemours. Jackson expressed dismay over the "backroom deal," which he claims guarantees nothing for North Carolina while West Virginia and New Jersey …

RBC bullish on Richemont as jewellery strength fuels earnings growth

Chemours (CC) Stock Looks Below Fair Value Even After A 51% Run

Chemours (CC) stock has surged 51.1% year-to-date, yet still appears undervalued according to several valuation tests, particularly when assessed using the Price-to-Sales (P/S) multiple. The stock trades at a significant discount (0.5x P/S) compared to its industry average (1.1x) and estimated fair value (1.1x), …

Share Your Thoughts on the EPA-Chemours PFAS Deal

Attorney General Jeff Jackson is urging North Carolinians to comment on the proposed EPA-Chemours PFAS deal, which he believes inadequately addresses the damage caused by Chemours in the state. The public comment period closes on July 29, and instructions are provided on how to …

Water contamination case near Fayetteville takes new turn

Chemours has reached an out-of-court settlement with over 2,600 residents who were suing the chemical company for water and land contamination near Fayetteville. This resolution marks a significant development in the multi-year legal battle.

Price to sales forward of HemoGenyx Pharmaceuticals Plc – LSE:HEMO

Reliance Chemotex promoter shares free of encumbrance in FY26

Is Now The Time To Look At Buying Compagnie Financière Richemont SA (VTX:CFR)?

Compagnie Financiere Richemont SA: Market Doesn't Seem To Appreciate The Fundamental Improvements Shown

Hemogenyx Pharmaceuticals PLC Announces Final Results

Insider Buyers At Hemogenyx Pharmaceuticals Sitting On UK£2.3m Profit